X0202 SCHEDULE 13G 0000924020 XXXXXXXX LIVE Common Stock, $0.0001 par value 10/13/2026 0002139097 TRex Bio, Inc. 89531N100 269 East Grand Avenue Suite 300 South San Francisco CA 94080 Rule 13d-1(c) Johnson & Johnson Innovation - JJDC, Inc. DE 0.00 1475302.00 0.00 1475302.00 1475302.00 N 5.3 CO JOHNSON & JOHNSON NJ 0.00 1475302.00 0.00 1475302.00 1475302.00 N 5.3 CO TRex Bio, Inc. 269 East Grand Avenue, Suite 300, South San Francisco, CA 94080 This Schedule 13G is filed by Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation ("JJDC"), and Johnson & Johnson, a New Jersey corporation ("J&J")(together, the "Reporting Persons"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being beneficially owned by JJDC and J&J are directly beneficially owned by JJDC, and J&J may be deemed to indirectly beneficially own such securities. The agreement between the Reporting Persons to file jointly (the "Joint Filing Agreement") is filed herewith as Exhibit A. JJDC: 410 George Street, New Brunswick, NJ 08901 J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 JJDC: DE J&J: NJ Y The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. Percentage ownership is based on 27,577,535 shares of Common Stock outstanding following the closing of the Issuer's initial public offering on October 13, 2026, as provided to the Reporting Persons by the Issuer. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Joint Filing Agreement Johnson & Johnson Innovation - JJDC, Inc. /s/ Jill McManus 10/15/2026 JOHNSON & JOHNSON /s/ Marc Larkins 10/15/2026